Targeting CD47 for cancer immunotherapy
Zhongxing Jiang(First Affiliated Hospital of Zhengzhou University), Yongping Song(First Affiliated Hospital of Zhengzhou University)
Cited by 342
Related Papers
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
|The Lancet Haematology|2019|248
Targeting macrophages in hematological malignancies: recent advances and future directions
|Journal of Hematology & Oncology|2022|162
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
|Journal of Hematology & Oncology|2020|50